PDCD1 and neoplasm: Immune checkpoint inhibitors can accurately occupy PD-1 or PD-L1 molecules, produce steric hindrance effect, hinder the binding of PD-1 and PD-L1, and restore immune responses inhibited by PD-1 pathway, including normal anti-tumor immune responses (8, 9).